Salute e Benessere
The 1-Year Follow-up Results of LuX-Valve Plus were Officially Released at TCT 2024
Safety results showed that the incidence of composite events remained low at 12.50%.
Efficacy results showed that TR grade, NYHA classification, and QoL improved significantly and continuously. At 1 year,
Professor Juan F. Granada concluded that LuX-Valve Plus system is a versatile TTVR device that does not depend on radial force for anchoring. Its innovative design (ventricular septal anchor & leaflet-grasping clips) provides optional mechanisms for anchoring and stability. The multicenter, TRAVEL II study showed that LuX-Valve Plus system is safe and effective in achieving short delivery times, low 1-year composite event rates, significant TR reduction and improvement in functional and QoL metrics at 1 year.
Additional studies in Europe and the U.S. using the LuX-Valve Plus system are underway, and more clinical results are expected to be released in the future. The Company is continuously advancing the global application of LuX-Valve series system to help more TR patients. As of the latest update, over 600 implantation cases have been completed worldwide with the LuX-Valve series products, and the longest follow-up record has been over 6 years.
View original content: https://www.prnewswire.co.uk/news-releases/the-1-year-follow-up-results-of-lux-valve-plus-were-officially-released-at-tct-2024-302293925.html